Logic-Driven
Molecular
Design.

MetalDrug operates at the frontier of deterministic molecular engineering. MDC, FDC, and the Moleculogic Engine function as a tiered, logic-verified simulation and generation platform — where every compound is traceable to its original logic blueprint.

1,274+Logic units generated since Jan 2025
B+Average entropy class across active blueprints
0Animal subjects in QRX-3 FDA submission
Blueprint MDC-2025-A7B9 VERIFIED
"logic_gates": [
  {
    "type": "AND",
    "inputs": [
      { "trigger": "pH", "condition": "<", "threshold": 6.5 },
      { "trigger": "ROS", "condition": ">", "threshold": 100 }
    ],
    "output": "ligand_release"
  }
],
"metal_center": {
  "element": "Zn",
  "coordination": "octahedral"
},
"scoring": {
  "entropy_class": "B+",
  "risk_level": "low",
  "confidence": 0.87
}
Entropy: B+ Risk: Low Confidence: 87%

Four stages from logic
directive to therapeutic deployment.

MetalDrug's core system functions as a tiered, logic-verified simulation platform. Each stage is deterministic, auditable, and traceable back to the original input directive.

01
Molecular Logic Definition

Users, scientists, or the SEI kernel define a molecular logic goal — for example, a compound that activates only under tumor-level pH and high ROS concentrations. This logic becomes the blueprint directive that drives all downstream generation.

// Input
Boolean trigger conditions, target tissue, therapeutic intent, constraint boundaries
02
Logic-to-Molecule Conversion

The Moleculogic Engine transforms the directive into candidate molecular structures via logic parsing, trigger-response mapping, and molecular candidate generation. Boolean logic gates — AND, OR, NOT, XOR — map directly to biochemical trigger mechanisms.

// Output
Candidate molecular structures with annotated trigger-response chains
03
SEI Scoring and Simulation

Each candidate undergoes deterministic simulation and scoring based on entropy class, risk level, and confidence score. The SEI (Sovereign Epistemic Intelligence) kernel evaluates ADMET profiles, DDI risk, and downstream clinical drift probability before any lab engagement.

// Metrics
Entropy class (A through D), risk level, confidence score, ADMET flags, clinical drift probability
04
MDC / FDC Therapeutic Deployment

Once validated, compounds are routed into MDC (metal-coordinated constructs) or FDC (fixed-dose combinations) depending on the target application. The final compound is traceable to its original logic blueprint and cryptographically anchored on ExergyNet L0.

// Output
ZK-anchored blueprint, eCTD-ready documentation, licensing-ready IP package

Biochemical triggers as
boolean logic gates.

Every molecule is defined by explicit trigger conditions, not black-box predictions. The gate fires only when all required environmental conditions are met simultaneously.

// Trigger Inputs
pH < 6.5 Tumor microenvironment acid threshold
ROS > 100 μM Reactive oxygen species concentration
Temp > 37.5°C Inflammatory thermal signature (optional)
AND
Gate
// Output Response
Ligand Release
Metal-ligand bond cleaves, releasing active payload in tumor site only
Metal Activation
Ru⁴⁺ center reduces to active Ru²⁺ oxidation state
Selectivity
Zero activation in healthy tissue — logic enforces specificity

Logic, not luck.

Unlike black-box drug discovery, MetalDrug builds every molecule on transparent logic, scientific reproducibility, and simulation-audited intent. Each compound is traceable back to its original blueprint, allowing transparent justification of mechanism and purpose to regulators and reviewers.

Transparent Mechanism of Action

Every causal link from trigger to therapeutic response is documented. Regulators see the logic chain, not a confidence number.

Reduced Off-Target Effects

Logic-driven design enforces selectivity at the architecture level. Off-target activation requires overriding explicit gate conditions.

Accelerated Discovery-to-Clinical Timeline

QRX-3 demonstrated 20-day IND remediation. The FDA accepted SEI-generated in silico data as definitive bridging evidence under Modernization Act 2.0.

// Blueprint MDC-Ru-216 · SEI Scoring
Binding Affinity
87%
ROS Selectivity
92%
Hepatorenal Safety
95%
pH Stability (pH 7.4)
89%
Clinical Drift Risk
12%
DDI Risk Score
8%
Entropy Class B+ Risk: Low · Confidence: 0.87 · ZK-Anchored

MDC and FDC — two
therapeutic deployment rails.

Once a blueprint passes SEI scoring, it routes into one of two deployment architectures depending on the target indication and mechanism requirements.

MDC
Metal Drug Conjugates

Coordination-driven therapeutic design leveraging metal-ligand interactions for programmable drug behavior. The metal center acts as a logic hub that responds to specific environmental triggers — pH, redox potential, ROS concentration — with precisely controlled release kinetics.

  • Oxidation state engineering (Ru²⁺/⁴⁺, Zn²⁺, Pt²⁺/⁴⁺)
  • Ligand exchange kinetics simulation
  • Aqueous stability profiling at physiological pH
  • Selectivity index computation vs healthy tissue
  • Metal center coordination geometry optimization
Access MDC Platform →
Ru⁴⁺ Complexes Zn²⁺ Conjugates Pt²⁺ Analogs Cu²⁺ Payloads
FDC
Fixed-Dose Combinations

Multi-agent therapeutic combinations governed by biochemical interaction tensors. Synergy surfaces are computed, not assumed. The QRX-3 CKD asset — Acetylcysteine, Ubiquinone, Pentoxifylline — demonstrated this architecture against the FDA with zero animal subjects.

  • Synergy surface mapping across agent combinations
  • DDI risk scoring (QSP-native, multi-organ modeling)
  • ADMET co-profiling for the combined agent stack
  • ICH-compliant CMC synthesis and excipient logic
  • LD50, NOAEL computation without animal data
Access FDC Platform →
Antioxidants Mitochondrial Agents Vasodilators Immunomodulators

ZK-verified compute on ExergyNet.

Every MetalDrug simulation dispatches to the ExergyNet prover swarm. RISC Zero zkVM generates a ZK-STARK cryptographic receipt for each computation — mathematical proof that the simulation ran correctly, settled in USDC on Base L2.

The result is a computation whose correctness is provable to any third party — regulator, investor, or counterparty — without re-running the work. This is the missing trust layer for regulatory science.

ZK-STARK Base L2 Solana RISC Zero
88.6%Cost reduction vs legacy cloud
32BOn-chain footprint per proof
USDCSettlement currency
L0ExergyNet Apex Router
Ed25519Signing key per blueprint
BCX-004MDC-Logic ELF circuit

Four tiers. Progressive
technology access.

MetalDrug offers a structured access model designed to accommodate different user needs — from public exploration to secure co-development environments with dedicated compute allocation.

Tier 0 · Public
Preview Mode

Public read-only access to daily blueprints and simplified molecular data. No account required.

  • Daily blueprint feed
  • Basic molecular visualization
  • Public publication access
  • AskMo Tier 0 queries
Explore Free →
Tier 1 · Researcher
Secure Sandbox

Secure environment for blueprint creation, ADMET simulation, and validation. NDA protected.

  • MDC Blueprint Builder
  • ADMET profiling
  • ExergyNet LIGHT compute
  • Blueprint export + NDA
Request Access →
Tier 2 · Scientific
Full Simulation

Advanced simulation with entropy scoring, IND draft generation, and ZK-anchored blueprints.

  • Full MDC + FDC simulation
  • SEI entropy scoring
  • IND package generation
  • ExergyNet HEAVY compute
Request Evaluation →
Tier 3–4 · Enterprise
Co-Development

Full partnership with licensing options, dedicated compute allocation, and IP co-anchoring.

  • Bulk API + private export
  • Co-development pipeline
  • LNES-04 Base L2 settlement
  • Platform-as-a-service licensing
Licensing Options →
// Access the Engine

Logic replaces
trial and error.

Request Tier 1 access. Your first blueprint is scored by SEI, anchored to ExergyNet L0 with your Ed25519 key, and cryptographically timestamped on submission. The logic is yours, permanently.